The anti-inflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the
peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam
blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the
migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent,
by the platelets.